Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 16, 2017 17:26 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies

WALTHAM, Mass., May 16, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing...
May 15, 2017 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals to Present at the 2017 UBS Global Healthcare Conference

WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer...
May 08, 2017 16:05 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Clinical and Business Update

Enrollment of second stage of melanoma cohort in Phase 2 ENCORE 601 trial proceeding ahead of schedule; expected to be completed in the third quarter Company to host conference call today at 4:30...
May 01, 2017 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax to Announce First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 8, 2017

WALTHAM, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its first quarter 2017 financial results on Monday, May 8, 2017, after the close of the...
April 27, 2017 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Announces Expansion of Immuno-Oncology Collaboration Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Colorectal Cancer

WALTHAM, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), today announced the expansion of ENCORE 601/KEYNOTE 142, the ongoing Phase 2 clinical collaboration...
April 20, 2017 16:05 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Announces Entinostat Data to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting

WALTHAM, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and...
April 04, 2017 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors

WALTHAM, Mass., April 04, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing...
March 29, 2017 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting

WALTHAM, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing...
March 02, 2017 16:05 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Reports Fourth Quarter and Year-end 2016 Financial Results and Provides Clinical and Business Update

Encore 601 refractory melanoma cohort to proceed to second stage of Phase 2; pre-specified objective response criteria satisfiedEnrollment of the first stage of both NSCLC cohorts completed; decision...
February 27, 2017 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

WALTHAM, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple...